Cagrilintide Peptide: Dosage, Protocol, and Reconstitution Guide
Cagrilintide Peptide
Cagrilintide is an investigational long-acting amylin analogue studied for appetite regulation, satiety, food intake, and weight management. Human clinical trials have evaluated cagrilintide both as a stand-alone treatment and in combination with semaglutide.
How Cagrilintide Works
Amylin-Receptor Signaling → Satiety ↑ + Food Intake ↓ + Gastric Emptying Effects → Weight-Management Research
Cagrilintide is a long-acting analogue of amylin, a pancreatic hormone involved in appetite and meal-related signaling. It is designed to prolong satiety and reduce food intake. Unlike GLP-1 receptor agonists, cagrilintide works primarily through amylin-related pathways, although it is being studied both alone and alongside GLP-1 therapy.
Cagrilintide is an amylin analogue, not a GLP-1 receptor agonist.
Human studies have evaluated once-weekly subcutaneous administration.
Clinical research has demonstrated dose-related reductions in body weight.
Gastrointestinal effects such as nausea, constipation, and diarrhea are among the most commonly reported adverse events.
Cagrilintide Research-Use Protocol
Important Evidence Distinction:
The protocol below preserves the commonly discussed research-use framework used on this site. Cagrilintide also has human clinical-trial dosing data, but the clinical studies used their own dose-escalation schedules, target doses, and treatment durations. The two should remain clearly separated.
The protocol below preserves the commonly discussed research-use framework used on this site. Cagrilintide also has human clinical-trial dosing data, but the clinical studies used their own dose-escalation schedules, target doses, and treatment durations. The two should remain clearly separated.
10 mg Vial + 3.0 mL BAC Water → 3.33 mg/mL → 1 Unit ≈ 33.3 mcg
Standard Research-Use Setup
Vial
10 mg
Water
3.0 mL bacteriostatic water
Concentration
3.33 mg/mL
Conversion
1 unit ≈ 33.3 mcg
Weeks 1–2
Start Low
Dose
0.6 mg
Units
18 units
Volume
0.18 mL
Weeks 3–4
Titration
Dose
1.2 mg
Units
36 units
Volume
0.36 mL
Weeks 5–6
Increased Response
Dose
2.4 mg
Units
72 units
Volume
0.72 mL
Weeks 7–16+
Higher Research-Use Range
Dose
4.5 mg
Units
135 units
Volume
1.35 mL
Protocol Details
Frequency
Once weekly
Injection Type
Subcutaneous
Research-Use Cycle
12–16+ weeks
Research-Use Titration
Dose increases every 2 weeks
Simple Structure:
The 0.6 → 1.2 → 2.4 → 4.5 mg progression shown above is a research-use framework. It should not be confused with a standardized clinical titration schedule, even though each of these dose levels has been represented in human cagrilintide research.
The 0.6 → 1.2 → 2.4 → 4.5 mg progression shown above is a research-use framework. It should not be confused with a standardized clinical titration schedule, even though each of these dose levels has been represented in human cagrilintide research.
What the Human Research Actually Used
Phase 2 Dose-Finding Trial
Doses Studied
0.3, 0.6, 1.2, 2.4, and 4.5 mg
Frequency
Once weekly
Route
Subcutaneous
Treatment Duration
26 weeks
Dose-Escalation Period
Up to 6 weeks
Phase 2 Weight-Loss Findings
Mean body-weight reduction ranged from approximately 6.0% to 10.8%
across the cagrilintide dose groups at 26 weeks.
The 4.5 mg group achieved approximately 10.8% mean weight reduction
in the trial-product analysis.
Weight reduction with 4.5 mg cagrilintide was greater than with
liraglutide 3.0 mg in that Phase 2 trial.
Why this matters:
Unlike many research-use peptide ranges, the 0.3–4.5 mg dose range has direct human clinical-trial precedent. However, the exact 2-week titration progression shown elsewhere on this page is still a separate research-use framework.
Unlike many research-use peptide ranges, the 0.3–4.5 mg dose range has direct human clinical-trial precedent. However, the exact 2-week titration progression shown elsewhere on this page is still a separate research-use framework.
Current Phase 3 Clinical Context
REDEFINE 1 — Cagrilintide Monotherapy Arm
Target Dose
2.4 mg once weekly
Treatment Duration
68 weeks
Mean Weight Reduction
≈ 11.8% with treatment adherence
Highest Dose at Week 68
82.5% remained at 2.4 mg
RENEW Phase 3 Program
Cagrilintide Dose
2.4 mg once weekly
RENEW 1
Obesity without type 2 diabetes
RENEW 2
Obesity with type 2 diabetes
Status
Phase 3 program initiated
Clinical Development Update:
Current development is focused heavily on 2.4 mg once-weekly cagrilintide monotherapy. This does not erase the earlier 4.5 mg Phase 2 data or the research-use framework above; it reflects the dose selected for current Phase 3 monotherapy development.
Current development is focused heavily on 2.4 mg once-weekly cagrilintide monotherapy. This does not erase the earlier 4.5 mg Phase 2 data or the research-use framework above; it reflects the dose selected for current Phase 3 monotherapy development.
How to Use Cagrilintide (Timing & Injection)
Injection TypeSubcutaneous
FrequencyOnce weekly
TimingConsistent weekly schedule
Specific Time of DayNo established requirement
Timing Notes
Human trials use once-weekly subcutaneous administration.
A specific morning or evening advantage has not been established.
The exact injection-site instructions depend on the clinical-trial preparation or future manufactured product.
Appetite, food intake, nausea, and gastrointestinal tolerance are important during dose escalation.
Reconstitution & Dose Conversion (10 mg Vial)
Research-Vial Context:
Cagrilintide used in Novo Nordisk clinical trials is a manufactured investigational study drug. The vial-and-BAC-water calculations below represent a research-use concentration framework and should not be interpreted as the clinical-trial formulation.
Cagrilintide used in Novo Nordisk clinical trials is a manufactured investigational study drug. The vial-and-BAC-water calculations below represent a research-use concentration framework and should not be interpreted as the clinical-trial formulation.
Example Research-Use Setup
Vial10 mg
Water3.0 mL bacteriostatic water
Concentration3.33 mg/mL
Conversion1 unit ≈ 33.3 mcg
Dose Reference
9 units ≈ 0.3 mg
18 units ≈ 0.6 mg
36 units ≈ 1.2 mg
72 units ≈ 2.4 mg
135 units ≈ 4.5 mg
Volume Note:
At approximately 3.33 mg/mL, a 4.5 mg amount equals about 1.35 mL. That exceeds the capacity of a standard 1 mL U-100 insulin syringe. This is a limitation of the example concentration, not the dose itself.
At approximately 3.33 mg/mL, a 4.5 mg amount equals about 1.35 mL. That exceeds the capacity of a standard 1 mL U-100 insulin syringe. This is a limitation of the example concentration, not the dose itself.
Storage & Shelf Life
Lyophilized (Unmixed Powder)
Short-term storage: keep refrigerated at 2–8°C / 36–46°F
Long-term storage: freeze at −20°C / −4°F
Estimated refrigerated shelf life: commonly ~12–24 months when sealed, dry, and protected from light
Estimated frozen shelf life: commonly up to ~2–3 years when stored properly
Keep sealed until ready to reconstitute
Protect from heat, sunlight, moisture, and repeated temperature swings
Do not repeatedly freeze and thaw the same vial
Reconstituted (Mixed)
After mixing: refrigerate at 2–8°C / 36–46°F
Best used within 30 days after reconstitution
Do not freeze after mixing
Avoid repeated temperature exposure
Discard if cloudy, discolored, or if particles appear
Research Material
Cagrilintide remains investigational, so there is no FDA-approved
commercial storage standard for independently prepared research vials.
Storage and stability depend on formulation, concentration, solvent,
purity, container, and manufacturer specifications.
Lyophilized research material is commonly stored refrigerated or frozen
according to supplier instructions.
Reconstituted research preparations are commonly refrigerated, but a
universal 30-day stability period has not been established for all formulations.
Cycle Length & Time Between Cycles
Research-Use Cycle → Reassess Tolerance & Intake → Continue, Pause, or Adjust
Research-Use Framework
Cycle Length
12–16+ weeks
Frequency
Once weekly
Research-Use Titration
Dose increases every 2 weeks
Commonly Discussed Break
2–4 weeks if cycling
Evidence Distinction:
The 12–16+ week research-use cycle and 2–4 week break are not established clinical requirements. Human cagrilintide trials have used longer, continuous treatment periods, including 26-week and 68-week studies.
The 12–16+ week research-use cycle and 2–4 week break are not established clinical requirements. Human cagrilintide trials have used longer, continuous treatment periods, including 26-week and 68-week studies.
Why Reassess?
Appetite suppression can substantially reduce total food intake.
Protein, fluid, and overall nutritional intake should remain adequate.
Persistent nausea, constipation, diarrhea, or vomiting can affect tolerability.
There is no evidence that a routine break is required to “reset” amylin signaling.
Monitoring During Use
Appetite, satiety, and total food intake
Body weight and waist circumference
Nausea, constipation, diarrhea, vomiting, or other GI effects
Hydration status
Protein intake and overall nutritional adequacy
Fatigue, dizziness, or symptoms associated with inadequate intake
Benefits & Research Findings
Human trials have demonstrated reductions in body weight across multiple once-weekly cagrilintide doses.
Phase 2 research demonstrated dose-related effects from 0.3 mg through 4.5 mg.
Cagrilintide 2.4 mg produced approximately 11.8% mean weight reduction at 68 weeks in the REDEFINE 1 monotherapy arm.
The amylin pathway provides an appetite-regulation mechanism distinct from GLP-1 receptor agonism.
Once-weekly administration has been used consistently across major human clinical studies.
Potential Side Effects & Safety Considerations
Nausea is among the most commonly reported adverse events.
Constipation, diarrhea, and vomiting have also been reported in human trials.
Administration-site reactions occurred in Phase 2 research.
Reduced appetite can become substantial and may contribute to inadequate nutritional intake.
Cagrilintide remains investigational, so long-term post-approval safety data are not available.
Best Practices
Increase research-use doses gradually rather than escalating aggressively.
Use a consistent weekly schedule.
Monitor gastrointestinal tolerance closely during escalation.
Maintain adequate hydration and nutritional intake.
Prioritize adequate protein during substantial appetite reduction and weight loss.
Do not assume the highest dose is necessary if appetite suppression or GI effects are already substantial.
Stacking Considerations
Amylin Pathway → Satiety ↑ → Combination Research With GLP-1 Pathways
Clinical Combination Evidence
Cagrilintide has substantial human combination research with semaglutide
as the investigational fixed-dose product CagriSema.
REDEFINE 1 studied cagrilintide 2.4 mg + semaglutide 2.4 mg once weekly
alongside each component individually.
CagriSema has been submitted to the FDA for weight-management approval,
but cagrilintide itself remains investigational.
Research-Use Combination Context
Cagrilintide is also discussed alongside tirzepatide, retatrutide, and
other appetite-regulating compounds in research-use settings.
Those combinations should not be assumed to have the same evidence base
as the clinically studied cagrilintide + semaglutide combination.
Combining multiple appetite-suppressing pathways can increase nausea,
gastrointestinal effects, and inadequate food intake.
Simple Rule:
Combination research should focus on controlled satiety and tolerability, not maximum appetite suppression. Cagrilintide already has a strong effect on food intake, so additional appetite-regulating compounds add both potential effects and additional uncertainty.
Combination research should focus on controlled satiety and tolerability, not maximum appetite suppression. Cagrilintide already has a strong effect on food intake, so additional appetite-regulating compounds add both potential effects and additional uncertainty.
Important Notes
Cagrilintide is an investigational long-acting amylin analogue and is not currently FDA-approved as a stand-alone treatment.
It is not a GLP-1 receptor agonist and works through a distinct appetite-regulation pathway.
Human Phase 2 research evaluated 0.3, 0.6, 1.2, 2.4, and 4.5 mg once weekly.
Current Phase 3 monotherapy development is focused on 2.4 mg once weekly.
The 0.6 → 1.2 → 2.4 → 4.5 mg progression shown on this page is preserved as a research-use framework and is not a standardized clinical titration schedule.
The 12–16+ week cycle and 2–4 week break are research-use conventions rather than established clinical requirements.
Cagrilintide has meaningful human combination evidence with semaglutide through the CagriSema clinical-development program.
Because appetite suppression can become substantial, nutritional intake and gastrointestinal tolerability are important considerations.
Important Disclaimer
Cagrilintide remains an investigational compound. The research-use dosing, reconstitution, and cycle information shown on this page is educational and should be distinguished from the manufactured investigational products and study-specific protocols used in controlled human clinical trials.
Comments
Post a Comment